Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Gel vs Triamcinolone for Minor Recurrent Aphthous Ulcers
NCT07672730Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Countries
- 1
- Sponsor
- Cairo University
- Drugs
- probiotic gel
- Conditions
- recurrent aphthous stomatitis (RAS)
01
Overview
Phase 4, randomised trial of probiotic gel in recurrent aphthous stomatitis (RAS) (2 arms), sponsored by Cairo University. Primary endpoints: Minor Recurrent Aphthous Ulcer Size at 2 weeks and Pain Severity at 2 weeks. Started Feb 2026; status: completed.
02
Design
2 arms- Study design
- Randomized
Group (1): Probiotic Gel Investigational Patient Group
Participants apply a thin layer of the experimental probiotic gel directly onto their minor recurrent aphthous ulcer lesion(s) four times daily.
Group (2): Triamcinolone Active Control Patient Group
Participants apply a thin layer of the triamcinolone gel directly onto the active minor aphthous ulcer lesion four times daily.
03
Who it enrols
Adults ≥18 years diagnosed with minor recurrent aphthous ulcers, excluding those with major or traumatic ulcers, recent steroid use (last 6 months), vulnerable groups, and pregnant or lactating women.
04
Endpoints
Primary
Minor Recurrent Aphthous Ulcer Size
Pain Severity
Secondary
Salivary microRNA-146a Expression
Beyond the preview
Go deeper on NCT07672730.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672730.